Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

Orna Therapeutics, part of a buzzy cohort of biotech companies established in the wake of the Covid pandemic, has cut more ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the ...

The firm has made significant strides in its RNA editing and RNA interference programs, which are attracting positive attention and positioning the company for differentiation in the treatment of ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

Texas A&M AgriLife researchers uncovered a promising target for controlling gene expression and other cellular processes, ...

TD Cowen analyst Ritu Baral maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $78.00. The company’s shares closed yesterday at $46.73. Baral covers ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...

Discover methods for accurate DNA and RNA quantification and learn how to analyze purity and concentration to enhance ...